Skip to main content
NCBI home page
Clinical and Experimental Immunology logoLink to Clinical and Experimental Immunology
. 1985 Dec;62(3):535–544.

Autoimmune disease and malignant lymphoma associated with host-versus-graft disease in mice.

M Tateno, N Kondo, T Itoh, T Yoshiki
PMCID: PMC1577477  PMID: 4085149

Abstract

BALB/c mice neonatally injected with (BALB/c X C57BL/6)F1 hybrid spleen cells develop host-versus-graft disease (HVGD) with immunopathological features characteristic of either systemic lupus erythematosus (SLE), or immunoblastic lymphadenopathy (IBL) in man. HVGD mice manifest polyclonal hypergammaglobulinemia with various autoantibodies, generalized lymphadenopathy, hepatosplenomegaly, immune complex glomerulonephritis and evolve in the end to malignant lymphoma. The necessary prerequisite for HVGD induction between donor and host can be summarized as follows: Histoincompatibilities in the H-2 region between donor and host are needed; predominant F1 donor cells needed for HVGD induction are, if not sole, steroid resistant, nylon wool nonadherent and Thy-1 positive T cells; the role of donor T cells is not only to present H-2 complex to the host, but also to interact with and proliferate in the host; strain differences are found for the susceptibility of HVGD induction in the host. It has been found that HVGD evolves to a malignant lymphoma of host T cell origin. The HVGD mouse model may, therefore, contribute to the understanding of the cell to cell interactions at work in the pathogenesis of IBL, as well as SLE, in man.

Full text

PDF
535

Images in this article

537Fig. 1
on p.537
541Fig. 3
on p.541

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Agnello V., Koffler D., Eisenberg J. W., Winchester R. J., Kundel H. G. C1g precipitins in the sera of patients with systemic lupus erythematosus and other hypocomplementemic states: characterization of high and low molecular weight types. J Exp Med. 1971 Sep 1;134(3 Pt 2):228s–241s. [PubMed] [Google Scholar]
  2. CELADA F., WELSHONS W. J. Demonstration of F1 hybrid anti-parent immunological reaction. Proc Natl Acad Sci U S A. 1962 Mar 15;48:326–331. doi: 10.1073/pnas.48.3.326. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Fialkow P. J., Gilchrist C., Allison A. C. Autoimmunity in chronic graft-versus-host disease. Clin Exp Immunol. 1973 Apr;13(4):479–486. [PMC free article] [PubMed] [Google Scholar]
  4. Frizzera G., Moran E. M., Rappaport H. Angio-immunoblastic lymphadenopathy with dysproteinaemia. Lancet. 1974 Jun 1;1(7866):1070–1073. doi: 10.1016/s0140-6736(74)90553-4. [DOI] [PubMed] [Google Scholar]
  5. Gleichmann E., Gleichmann H., Wilke W. Autoimmunization and lymphomagenesis in parent to F1 combinations differing at the major histocompatibility complex: model for spontaneous disease caused by altered self-antigens? Transplant Rev. 1976;31:156–224. doi: 10.1111/j.1600-065x.1976.tb01454.x. [DOI] [PubMed] [Google Scholar]
  6. Goldman M., Feng H. M., Engers H., Hochman A., Louis J., Lambert P. H. Autoimmunity and immune complex disease after neonatal induction of transplantation tolerance in mice. J Immunol. 1983 Jul;131(1):251–258. [PubMed] [Google Scholar]
  7. Goldman M., Rose L. M., Hochmann A., Lambert P. H. Deposition of idiotype-anti-idiotype immune complexes in renal glomeruli after polyclonal B cell activation. J Exp Med. 1982 May 1;155(5):1385–1399. doi: 10.1084/jem.155.5.1385. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Hard R. C., Jr, Kullgren B. Etiology, pathogenesis, and prevention of a fatal host-versus-graft syndrome in parent-F1 mouse chimeras. Am J Pathol. 1970 May;59(2):203–224. [PMC free article] [PubMed] [Google Scholar]
  9. Hard R. C., Jr, Moncure C. W., Still W. J. Renal lesions with organized deposits and lipid as part of the host versus graft syndrome in parent-F 1 mouse chimeras. Lab Invest. 1973 Apr;28(4):468–476. [PubMed] [Google Scholar]
  10. Hard R. C., Jr, Still W. J. Intravascular fibrin deposits, hepatic infarcts and thrombocytopenia in parent/F mouse chimeras with host-versus-graft syndrome. Am J Pathol. 1975 Apr;79(1):131–146. [PMC free article] [PubMed] [Google Scholar]
  11. Hellström I., Hellström K. E., Allison A. C. Neonatally induced allograft tolerance may be mediated by serum-borne factors. Nature. 1971 Mar 5;230(5288):49–50. doi: 10.1038/230049a0. [DOI] [PubMed] [Google Scholar]
  12. Hirsch M. S., Black P. H., Tracy G. S., Leibowitz S., Schwartz R. S. Leukemia virus activation in chronic allogeneic disease. Proc Natl Acad Sci U S A. 1970 Dec;67(4):1914–1917. doi: 10.1073/pnas.67.4.1914. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Izui S., Lambert P. H., Fournié G. J., Türler H., Miescher P. A. Features of systemic lupus erythematosus in mice injected with bacterial lipopolysaccharides: identificantion of circulating DNA and renal localization of DNA-anti-DNA complexes. J Exp Med. 1977 May 1;145(5):1115–1130. doi: 10.1084/jem.145.5.1115. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Izui S., McConahey P. J., Theofilopoulos A. N., Dixon F. J. Association of circulating retroviral gp70-anti-gp70 immune complexes with murine systemic lupus erythematosus. J Exp Med. 1979 May 1;149(5):1099–1116. doi: 10.1084/jem.149.5.1099. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Klassen L. W., Krakauer R. S., Steinberg A. D. Selective loss of suppressor cell function in New Zealand mice induced by NTA. J Immunol. 1977 Sep;119(3):830–830. [PubMed] [Google Scholar]
  16. Lampert P. W., Oldstone M. B. Host immunoglobulin G and complement deposits in the choroid plexus during spontaneous immune complex disease. Science. 1973 Apr 27;180(4084):408–410. doi: 10.1126/science.180.4084.408. [DOI] [PubMed] [Google Scholar]
  17. Lukes R. J., Tindle B. H. Immunoblastic lymphadenopathy. A hyperimmune entity resembling Hodgkin's disease. N Engl J Med. 1975 Jan 2;292(1):1–8. doi: 10.1056/NEJM197501022920101. [DOI] [PubMed] [Google Scholar]
  18. Maruyama N., Furukawa F., Nakai Y., Sasaki Y., Ohta K., Ozaki S., Hirose S., Shirai T. Genetic studies of autoimmunity in New Zealand mice. IV. Contribution of NZB and NZW genes to the spontaneous occurrence of retroviral gp70 immune complexes in (NZB X NZW)F1 hybrid and the correlation to renal disease. J Immunol. 1983 Feb;130(2):740–746. [PubMed] [Google Scholar]
  19. McCullagh P. Anti-parental-strain lymphocyte responsiveness of F1 hybrid-strain lymphocytes. Scand J Immunol. 1977;6(10):967–980. doi: 10.1111/j.1365-3083.1977.tb00332.x. [DOI] [PubMed] [Google Scholar]
  20. Nakano K., Nakamura I., Cudkowicz G. Generation of F1 hybrid cytotoxic T lymphocytes specific for self H-2. Nature. 1981 Feb 12;289(5798):559–563. doi: 10.1038/289559a0. [DOI] [PubMed] [Google Scholar]
  21. Olding L. B., Jensen F. C., Oldstone M. B. Pathogenesis of of cytomegalovirus infection. I. Activation of virus from bone marrow-derived lymphocytes by in vitro allogenic reaction. J Exp Med. 1975 Mar 1;141(3):561–572. doi: 10.1084/jem.141.3.561. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Pangalis G. A., Moran E. M., Nathwani B. N., Zelman R. J., Kim H., Rappaport H. Angioimmunoblastic lymphadenopathy. Long-term follow-up study. Cancer. 1983 Jul 15;52(2):318–321. doi: 10.1002/1097-0142(19830715)52:2<318::aid-cncr2820520221>3.0.co;2-g. [DOI] [PubMed] [Google Scholar]
  23. Primi D., Hammarström L., Smith C. I., Möller G. Characterization of self-reactive B cells by polyclonal B-cell activators. J Exp Med. 1977 Jan 1;145(1):21–30. doi: 10.1084/jem.145.1.21. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Rolink A. G., Radaszkiewicz T., Pals S. T., van der Meer W. G., Gleichmann E. Allosuppressor and allohelper T cells in acute and chronic graft-vs-host disease. I. Alloreactive suppressor cells rather than killer T cells appear to be the decisive effector cells in lethal graft-vs.-host disease. J Exp Med. 1982 May 1;155(5):1501–1522. doi: 10.1084/jem.155.5.1501. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Rosén A., Gergely P., Jondal M., Klein G., Britton S. Polyclonal Ig production after Epstein-Barr virus infection of human lymphocytes in vitro. Nature. 1977 May 5;267(5606):52–54. doi: 10.1038/267052a0. [DOI] [PubMed] [Google Scholar]
  26. Schauer P. K., Straus D. J., Bagley C. M., Jr, Rudolph R. H., McCracken J. D., Huff J., Glucksburg H., Bauermeister D. E., Clarkson B. D. Angioimmunoblastic lymphadenopathy: clinical spectrum of disease. Cancer. 1981 Dec 1;48(11):2493–2498. doi: 10.1002/1097-0142(19811201)48:11<2493::aid-cncr2820481124>3.0.co;2-t. [DOI] [PubMed] [Google Scholar]
  27. Shirai T., Hayakawa K., Okumura K., Tada T. Differential cytotoxic effect of natural thymocytotoxic autoantibody of NZB mice on functional subsets of T cells. J Immunol. 1978 Jun;120(6):1924–1929. [PubMed] [Google Scholar]
  28. Shirai T., Mellors R. C. Natural cytotoxic autoantibody against thymocytes in NZB mice. Clin Exp Immunol. 1972 Sep;12(1):133–152. [PMC free article] [PubMed] [Google Scholar]
  29. Shirai T., Yoshiki T., Mellors R. C. Thymus dependence of cells in peripheral lymphoid tissues and in the circulation sensitive to natural thymocytotoxic autoantibody in NZB mice. J Immunol. 1972 Jul;109(1):32–37. [PubMed] [Google Scholar]
  30. Simpson E., O'Hopp S., Harrison M., Mosier D., Melief K., Cantor H. Immunological disease induced by injecting F1 lymphoid cells into certain parental strains. Immunology. 1974 Dec;27(6):989–1007. [PMC free article] [PubMed] [Google Scholar]
  31. Taylor R. B., Basten A. Suppressor cells in humoral immunity and tolerance. Br Med Bull. 1976 May;32(2):152–157. doi: 10.1093/oxfordjournals.bmb.a071348. [DOI] [PubMed] [Google Scholar]
  32. Voisin G. A., Kinsky R. G., Duc H. T. Immune status of mice tolerant of living cells. II. Continuous presence and nature of facilitation-enhancing antibodies in tolerant animals. J Exp Med. 1972 May 1;135(5):1185–1203. doi: 10.1084/jem.135.5.1185. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Waterfield J. D., Bick P. H., Möller E., Möller G. Presence of alloantigen-reactive cells in neonatally tolerized mice. Scand J Immunol. 1978;7(5):435–438. doi: 10.1111/j.1365-3083.1978.tb00475.x. [DOI] [PubMed] [Google Scholar]
  34. Yoshiki T., Hayasaka T., Fukatsu R., Shirai T., Itoh T., Ikeda H., Katagiri M. The structural proteins of murine leukemia virus and the pathogenesis of necrotizing arteritis and glomerulonephritis in SL/Ni mice. J Immunol. 1979 May;122(5):1812–1820. [PubMed] [Google Scholar]
  35. Yoshiki T., Mellors R. C., Strand M., August J. T. The viral envelope glycoprotein of murine leukemia virus and the pathogenesis of immune complex glomerulonephritis of New Zealand mice. J Exp Med. 1974 Oct 1;140(4):1011–1027. doi: 10.1084/jem.140.4.1011. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Clinical and Experimental Immunology are provided here courtesy of British Society for Immunology

RESOURCES